Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of Europe, Canada, Australia and China Agreement Adds
Takeda Pharmaceutical (TAK) and Arrowhead (ARWR) Announce Publication of Results from Phase 2 Study of Fazirsiran streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire Adaptate Biotherapeutics (“Adaptate”), a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vd1) gamma delta (?d) T cells.
Acquisition expands Takeda's immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging gamma-delta T cells for the potential treatment of solid tumors and hematological